Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2019-nCoV subunit vaccine composition and immunization method thereof

A 2019-ncov, subunit vaccine technology, applied in biochemical equipment and methods, microorganisms, pharmaceutical formulations, etc., can solve problems that have not yet been raised

Active Publication Date: 2020-07-07
陈宛莎
View PDF4 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] To the best of our knowledge, no intranasal administration of a coronavirus capsid subunit vaccine has been proposed so far, which would be an effective means of conferring protection against infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2019-nCoV subunit vaccine composition and immunization method thereof
  • 2019-nCoV subunit vaccine composition and immunization method thereof
  • 2019-nCoV subunit vaccine composition and immunization method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1 Computer simulation specific process of S glycoprotein binding to human ACE2 receptor

[0086] The 2019-nCoV virus S glycoprotein is a precursor protein consisting of about 1,300 amino acids, which can be cleaved into an amino (N)-terminal receptor-binding subunit S1 (about 700 amino acids) and a carboxy (C)-terminal Fusion subunit S2 (about 600 amino acids). The S1 subunit contains the receptor ACE2 binding domain (RBD), and the S2 subunit contains a hydrophobic fusion peptide and two heptad repeat regions. The 2019-nCoV glycoprotein has two distinct protease cleavage sites: the S1 / S2 cleavage site is located between residues 660-675 of the precursor protein, while the S2' cleavage site is on the S2 subunit. Therefore, the key site that interferes with the binding of the S1 subunit of 2019-nCoV to the human ACE2 receptor is before residues 660-675.

[0087] We report the computer simulation structure of the 2019-nCoV glycoprotein binding to the human ACE2 r...

Embodiment 2

[0093] The preparation of embodiment 2 gel emulsifier

[0094] Weigh 3.0 g of dipalmitoylphosphatidylcholine into a 50 mL beaker, add 1.2 g of oleic acid and mix together to form a uniform paste.

[0095] Add 0.72 g of arginine to 30 mL of distilled deionized water and add it to dipalmitoylphosphatidylcholine oleic acid paste and heat to 45 °C. Mixed by magnetic stirring, the mixture forms a transparent and stable gel. Store the gel.

[0096] Take 100 mL of gel, add 2 mg of synthesized and purified glycoprotein, stir magnetically for 3 minutes, shake in an ultrasonic water bath for 15 minutes, dispense into vials of 20 μg per mL, for 1 person, and store in a refrigerator at 4°C.

Embodiment 3

[0097] The preparation of embodiment 3 liposomes

[0098] 120 g dipalmitoylphosphatidylcholine and 24 g oleic acid were added together and mixed well until a white homogeneous paste was observed.

[0099] Then 2 mg of arginine was dissolved in 60 mL of phosphate buffered saline (ionic strength = 0.15, pH = 7.4).

[0100] The arginine salt solution was added to the paste and heated to 40°C for 1 hour, or until a slightly cloudy solution was observed.

[0101] Take 100 mL of liposome suspension, add 2 mg of synthesized and purified glycoprotein, stir magnetically for 3 minutes, shake in an ultrasonic water bath for 15 minutes, dispense into vials of 20 μg per mL, for 1 person, and store in a refrigerator at 4°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a 2019-nCoV subunit vaccine composition and an immunization method thereof. The vaccine composition is a surfaceglycoprotein subunit vaccine of fusion protein consisting of one or more surface glycoprotein subunits obtained from a 2019-nCoV virus strain and a TAT transmembrane sequence, is assisted by non-toxicglucopyranosyl lipid as an adjuvant, and is coated with liposome or exosome. The vaccine composition has the advantages of high antigen presentation efficiency, no toxic or side effect on a human body and no stimulation effect.

Description

technical field [0001] The invention belongs to the technical field of drugs and vaccine compositions, and in particular relates to a 2019-nCoV subunit vaccine composition and an immunization method thereof. Background technique [0002] Coronaviruses belong to the genus Coronaviridae of the Coronaviridae family and are a class of large, enveloped, positive-strand RNA viruses. The genome size of coronaviruses is about 27 to 32 kilobases, the longest among known RNA viruses. Coronaviruses mainly infect the upper respiratory tract or gastrointestinal tract of mammals and birds, and can cause diseases of the upper respiratory tract, gastrointestinal tract and central nervous system in humans and other animals. Commonly found in livestock and domestic pets, coronaviruses can cause severe infectious disease and pose a threat to agriculture. For example, avian infectious bronchitis virus (IBV) mainly causes respiratory disease in chickens and seriously affects the poultry indust...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/215A61P31/14
CPCA61K39/12A61K2039/54A61K2039/543A61K2039/55572A61P31/14C12N2770/20034
Inventor 陈宛莎
Owner 陈宛莎
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com